| pubmed-article:17554385 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17554385 | lifeskim:mentions | umls-concept:C0038250 | lld:lifeskim |
| pubmed-article:17554385 | lifeskim:mentions | umls-concept:C0023473 | lld:lifeskim |
| pubmed-article:17554385 | lifeskim:mentions | umls-concept:C0389995 | lld:lifeskim |
| pubmed-article:17554385 | lifeskim:mentions | umls-concept:C0935989 | lld:lifeskim |
| pubmed-article:17554385 | lifeskim:mentions | umls-concept:C1332710 | lld:lifeskim |
| pubmed-article:17554385 | lifeskim:mentions | umls-concept:C1551336 | lld:lifeskim |
| pubmed-article:17554385 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:17554385 | lifeskim:mentions | umls-concept:C1552913 | lld:lifeskim |
| pubmed-article:17554385 | lifeskim:mentions | umls-concept:C0062068 | lld:lifeskim |
| pubmed-article:17554385 | lifeskim:mentions | umls-concept:C2348480 | lld:lifeskim |
| pubmed-article:17554385 | lifeskim:mentions | umls-concept:C0667301 | lld:lifeskim |
| pubmed-article:17554385 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:17554385 | pubmed:dateCreated | 2007-7-19 | lld:pubmed |
| pubmed-article:17554385 | pubmed:abstractText | Evidence from cell line-based studies indicates that rho-kinase may play a role in the leukaemic transformation of human cells mediated by the BCR/ABL tyrosine kinase, manifest clinically as chronic myeloid leukaemia (CML). We therefore employed two separate inhibitors, Y-27632 and fasudil, to inhibit the activity of rho-kinase against ex vivo CD34(+) cells collected from patients with CML. We compared the effects of rho-kinase inhibition in those cells with the effects of direct inhibition of BCR/ABL using the specific inhibitor imatinib. We found that inhibition of rho-kinase inhibited the effective proliferation, and reduced survival of CML progenitor cells. When combined with imatinib, rho-kinase inhibition added to the anti-proliferative and pro-apoptotic effects of the BCR/ABL inhibitor. Our studies may indicate therapeutic benefit in some cases for the combination of rho-kinase inhibitors with imatinib. | lld:pubmed |
| pubmed-article:17554385 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17554385 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17554385 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17554385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17554385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17554385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17554385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17554385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17554385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17554385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17554385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17554385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17554385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17554385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17554385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17554385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17554385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17554385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17554385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17554385 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17554385 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17554385 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:17554385 | pubmed:issn | 0887-6924 | lld:pubmed |
| pubmed-article:17554385 | pubmed:author | pubmed-author:AdamsJJ | lld:pubmed |
| pubmed-article:17554385 | pubmed:author | pubmed-author:SpooncerEE | lld:pubmed |
| pubmed-article:17554385 | pubmed:author | pubmed-author:WhettonA DAD | lld:pubmed |
| pubmed-article:17554385 | pubmed:author | pubmed-author:LucasG SGS | lld:pubmed |
| pubmed-article:17554385 | pubmed:author | pubmed-author:BurthemJJ | lld:pubmed |
| pubmed-article:17554385 | pubmed:author | pubmed-author:MottramRR | lld:pubmed |
| pubmed-article:17554385 | pubmed:author | pubmed-author:Rees-UnwinKK | lld:pubmed |
| pubmed-article:17554385 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17554385 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:17554385 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17554385 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17554385 | pubmed:pagination | 1708-14 | lld:pubmed |
| pubmed-article:17554385 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:meshHeading | pubmed-meshheading:17554385... | lld:pubmed |
| pubmed-article:17554385 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17554385 | pubmed:articleTitle | The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells. | lld:pubmed |
| pubmed-article:17554385 | pubmed:affiliation | Division of Laboratory and Regenerative Medicine, Stopford Building, Manchester, UK. john.burthem@cmmc.nhs.uk | lld:pubmed |
| pubmed-article:17554385 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17554385 | lld:pubmed |
